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Abstract SWOG S0800, a randomized open-label Phase II
clinical trial, compared the combination of weekly nab-pa-
clitaxel and bevacizumab followed by dose-dense doxoru-
bicin and cyclophosphamide (AC) with nab-paclitaxel
followed or preceded by AC as neoadjuvant treatment for
HER2-negative locally advanced breast cancer (LABC) or
inflammatory breast cancer (IBC). Patients were randomly
allocated (2:1:1) to three neoadjuvant chemotherapy arms:
(1) nab-paclitaxel with concurrent bevacizumab followed by
AC; (2) nab-paclitaxel followed by AC; or (3) AC followed
by nab-paclitaxel. The primary endpoint was pathologic
complete response (pCR) with stratification by disease type
(non-IBC LABC vs. IBC) and hormone receptor status
(positive vs. negative). Overall survival (OS), event-free
survival (EFS), and toxicity were secondary endpoints.
Analyses were intent-to-treat comparing bevacizumab to the
combined control arms. A total of 215 patients were accrued
including 11 % with IBC and 32 % with triple-negative
breast cancer (TNBC). The addition of bevacizumab
significantly increased the pCR rate overall (36 vs. 21 %;
p = 0.019) and in TNBC (59 vs. 29 %; p = 0.014), but not
in hormone receptor-positive disease (24 vs. 18 %;
p = 0.41). Sequence of administration of nab-paclitaxel and
AC did not affect the pCR rate. While no significant differ-
ences in OS or EFSwere seen, a trend favored the addition of
bevacizumab for EFS (p = 0.06) in TNBC. Overall, Grade
3–4 adverse events did not differ substantially by treatment
arm. The addition of bevacizumab to nab-paclitaxel prior to
dose-dense AC neoadjuvant chemotherapy significantly
improved the pCR rate compared to chemotherapy alone in
patients with triple-negative LABC/IBC and was accompa-
nied by a trend for improved EFS. This suggests reconsid-
eration of the role of bevacizumab in high-risk triple-
negative locally advanced breast cancer.
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Introduction
Locally advanced breast cancer (LABC) was historically
defined as cancers that were inoperable, T4 and/or
advanced regional nodal disease at presentation, and had
poor survival outcomes with locoregional therapy alone.
However, the definition has expanded to include potentially
operable tumors greater than 5 cm [1–3]. Inflammatory
breast cancer (IBC) characterized by diffuse erythema or
edema of the affected breast, with or without histologically
confirmed involvement of the dermal lymphatics, is a
highly aggressive form of LABC that has poor prognosis,
with 10-year disease-free survival rates reported at
20–25 % [4]. Few randomized studies have targeted LABC
and/or IBC and most large adjuvant and neoadjuvant trials
exclude these patients. Anthracycline- and taxane-based
neoadjuvant chemotherapy represents the standard of care
for LABC. Pathologic complete response (pCR), com-
monly defined as the absence of residual invasive cancer in
both the breast and axillary lymph nodes, has emerged as a
surrogate endpoint for disease-free and overall survival, as
the achievement of a pCR is associated with a favorable
long-term prognosis in all breast cancer subtypes, while
extensive residual disease predicts for poor outcomes,
especially in triple-negative [estrogen receptor (ER), pro-
gesterone receptor (PgR) and human epidermal growth
factor receptor 2 (HER2) negative] and HER2-positive
breast cancers [5–7].
Angiogenesis is believed to play a significant role in
LABC/IBC [8–12]. Bevacizumab is a recombinant,
humanized, monoclonal antibody that binds and neutralizes
the vascular endothelial growth factor A, thus acting as an
antiangiogenic agent. Bevacizumab has activity in multiple
advanced neoplasms, including breast cancer [12–17].
However, after initial enthusiasm over the combination of
bevacizumab with chemotherapy in the metastatic setting,
subsequent analyses suggested that bevacizumab produces
more toxicity than benefit, and initial accelerated approval
for the drug in this setting was subsequently withdrawn by
the Food and Drug Administration (FDA) [18]. In addition,
two prospective randomized trials failed to document
benefit for the addition of bevacizumab to adjuvant
chemotherapy in any subset of breast cancer patients
[19, 20].
However, in the initial metastatic trials, bevacizumab
showed activity in some patients when administered with
chemotherapy [21]. Despite suggestions that patients with
ER/PgR-positive and those with triple-negative cancers
may benefit from the addition of bevacizumab [25–28];
retrospective analyses have failed to identify predictive
biomarkers that might permit more efficient use of this
agent [22]. Therefore, in the current trial (SWOG0800-
ClinicalTrials.gov NCT00856492), we prospectively
examined whether neoadjuvant bevacizumab might be
more active within selected intrinsic subtypes when
administered with neoadjuvant chemotherapy. Further-
more, the vascular pruning hypothesis proposed by Jain
suggests that antiangiogenesis might improve flow and
oxygenation and enhance the delivery and proapoptotic
effect of certain chemotherapy agents, in particular the
taxanes [17, 23]. Thus, we considered whether the addition
of bevacizumab to neoadjuvant weekly nab-paclitaxel fol-
lowed by dose-dense doxorubicin and cyclophosphamide
(‘‘AC’’) would increase the pCR rates in patients with
HER2-negative LABC/IBC. Nab-paclitaxel was chosen as
the taxane backbone based on several advantages compared
to paclitaxel at the time of trial initiation, including
increased intratumoral drug levels [24], albumin-mediated
receptor transport of the drug via secreted protein acidic and
rich in cysteine (SPARC)/osteonectin [25] overexpressed in
around 55 % of primary breast tumors [26], specific
receptor-mediated transport mechanisms due to overex-
pression of caveolin-1 and -2 in IBC [27], and antiangio-
genic activity as well as synergistic activity with
antiangiogenic agents [28, 29]. More recently, Nab-pacli-
taxel was shown to be more effective than conventional
paclitaxel as part of a neoadjuvant regimen for patients with
high-risk early breast cancer in a large German study, the
GeparSepto [30]. This study found that 38 % of patients
who received nab-paclitaxel during the randomized phase
III trial achieved a pCR, compared with 29 % of partici-
pants who were given conventional paclitaxel, p\ 0.001.
Patients and methods
Patient population and selection criteria
Eligible patients were women with biopsy-confirmed,
previously untreated, clinical stage IIB to IIIC HER-2-
negative breast carcinoma and known hormone receptor
status. HER-2 status was determined locally according to
the 2007 American Society of Clinical Oncology/College
of American Pathology guidelines [31]. The clinical diag-
nosis of IBC (T4d) was based on AJCC cancer staging
criteria. Patients had to have a Zubrod Performance Status
of 0–2 and adequate hematologic, renal, and hepatic
function. Patients over the age of 60 or with a history of
hypertension were required to have a normal echocardio-
gram or multigated acquisition scan (MUGA). Patients
were not permitted to have pre-existing peripheral neu-
ropathy grade[2, be pregnant or nursing, or have a history
of a cerebrovascular accident, transient ischemic attack, or
cardiac event within 12 months prior to registration.
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Treatment plan
Figure 1 illustrates the treatment schema. Patients were
randomly assigned to Arm 1, 2, or 3 in a 2:1:1 ratio
according to a dynamic allocation scheme based on two
stratification factors (1) IBC vs. not and (2) hormone
receptor-positive (ER/PgR?) vs. triple-negative breast
cancer (TNBC).
Patients randomized to treatment on Arm 1 (beva-
cizumab) received intravenous (IV) administration of nab-
paclitaxel 100 mg/m2 IV weekly for 12 weeks (nP 9 12)
with IV bevacizumab 10 mg/kg every 2 weeks (six doses),
followed by IV doxorubicin 60 mg/m2 and cyclophos-
phamide 600 mg/m2 with pegfilgrastim 6 mg subcuta-
neously every 2 weeks for six cycles (ddAC 9 6). Patients
randomized to Arm 2 received nP 9 12 followed by ddAC
9 6, and those randomized to Arm 3 received ddAC 9 6
first followed by nP 9 12, both without bevacizumab. The
use of six cycles of AC was based on a similar therapy
duration used in a parallel adjuvant SWOG study S0221
[32]. At the time when the study was initiated, the use of
six cycles of doxorubicin and cyclophosphamide was
common in breast cancer clinical trials [33, 34]. The ideal
duration of adjuvant doxorubicin chemotherapy for
patients with breast cancer, especially those with LABC, is
not known. The results of the Cancer and Leukemia Group
B trial 40101 conducted using a phase III factorial design,
to define whether six cycles of a chemotherapy regimen are
superior to four cycles, were not yet known [Shulman,
2014#5657]. The dose of nab-paclitaxel was chosen based
on studies at the time showing that weekly administration
of 100 mg/m2 nab-paclitaxel as single agent showed the
same antitumor activity as 125 mg/m2, with the benefit of a
more favorable toxicity profile in patients with advanced
disease [35]. NCI Common Terminology Criteria for
Adverse Events (CTCAE) Version 4.0 was utilized for
adverse event reporting and toxicity monitoring. The
bevacizumab dose was never reduced, but treatment was
held for uncontrolled hypertension or any grade 3 toxicity
attributed to this agent and permanently discontinued for
grade 3 hypertension not controlled medically. If the study
treatment was interrupted for more than 3 consecutive
weeks, the patient was taken off the study.
Surgical management
Surgery was performed within 3–6 weeks after completion
of neoadjuvant chemotherapy. Patients with LABC who
had an excellent clinical response could undergo breast-
conserving surgery, but mastectomy was required for
patients with IBC regardless of their response to treatment.
Postneoadjuvant axillary staging was required for all
patients. In clinical N0 patients, a sentinel node (SN)
biopsy procedure was allowed; in patients who were still
clinically node-positive and those with a positive SN
biopsy, a full axillary lymph node dissection was required.
Patients who progressed on study treatment were removed
from protocol treatment. Postlumpectomy and postmas-
tectomy standard breast radiation therapy (RT) was
required irrespective of pathological response [36].
Pathologic evaluation
Pathologic response was determined by local pathologists
who were instructed on the study definition of pCR. Sur-
gical pathology reports were reviewed centrally for accu-
racy of coding by the study chair (Z.N.) without the
knowledge of treatment assignment. pCR was defined as
Fig. 1 Schema of randomized Phase II SWOG S0800 trial
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the absence of residual invasive disease with or without
ductal carcinoma in situ (ypT0/isN0) in breast and axilla.
Specific procedures were provided for evaluation of sur-
gical specimens following neoadjuvant therapy
(Appendix).
Statistical analysis
SWOG S0800 was a randomized Phase II trial comparing
the experimental bevacizumab arm (Arm 1) with the con-
trol (no bevacizumab) arms (Arms 2 and 3). Accrual was
expected to take 2 years with a planned follow-up of two
additional years. Based on SWOG study S0012 with sim-
ilar patients and similar chemotherapy backbone [37], we
estimated that the control pCR rate would be 25 %, and
that a sample size of 200 would allow detection of an
increase of 15 % in pCR rate to 40 %. Power was 80 % (1-
sided a = 0.10) for the primary comparison of beva-
cizumab versus no bevacizumab (collapsing over the two
sequences). Dynamic balancing was used to adjust the
randomization probabilities so that patient allocation was
balanced within each stratum. Near the end of the trial an
incorrect adjustment by SWOG programming staff dis-
turbed the dynamic balancing allocation, causing more
patients to be assigned to Arm 2 and fewer to Arm 3 than
intended. However, this did not affect the primary com-
parison of pCR rates between bevacizumab versus no
bevacizumab. Analysis was intent-to-treat of eligible
patients which is the SWOG standard approach [38].
The secondary randomization of sequence between
Arms 2 and 3 was conducted to allow study of the impact
of potential predictive biomarkers such as SPARC proteins.
There was no expectation of a difference in pCR due to the
sequencing, and the primary statistical plan was to compare
the intervention arm to the combined control arms. Pre-
dictive longitudinal biomarker studies are being conducted
comparing all three arms and will be reported separately
[39].
Overall survival (OS) was a secondary endpoint defined
as the time from registration to death due to any cause. We
also analyzed event-free survival (EFS) starting at the time
of registration. Events included progression prior to sur-
gery, recurrence postsurgery, or death from any cause.
Patients without an event were censored at the last known
follow-up time. OS and EFS were analyzed using stratified
log-rank tests and Cox regression.
The third objective was to explore for an interaction
between bevacizumab and the stratification factors on pCR.
A Cochran–Mantel–Haenszel test was performed for the
primary analysis comparing pCR rates between the beva-
cizumab and no bevacizumab groups adjusting for the
stratifying variables. We then used logistic regression to
explore for an interaction of treatment with type of disease
and ER/PgR status. The SWOG Data and Safety Moni-
toring Committee reviewed the study every 6 months for
safety, but no interim analyses were planned or conducted.
Results
Patient characteristics
Between May 2010 and September 2012, 215 patients from
SWOG member institutions were enrolled and randomized.
Two patients were deemed ineligible due to clinical Stage
IIA disease and two more withdrew consent leaving 211
patients for analysis. The final allocation of analyzable
patients was 98, 62, and 51 in Arms 1, 2, and 3, respec-
tively (Fig. 2).
Baseline characteristics of the patients and their tumors
are provided in Table 1. The vast majority of the partici-
pants had non-inflammatory LABC (89 %), whereas only
11 % had IBC. Sixty-eight percent of tumors were ER/
PgR?.
Primary outcome
Table 2 shows pCR rates by randomized group and pre-
defined patient subsets. Seventeen (8 %) patients had either
no definitive surgery (n = 15) or an incomplete pathology
report (n = 2), and were coded as no pCR in the intention-
to-treat analyses. At the time of surgery, 135 (64 %) of the
211 patients had residual invasive disease (no pCR) and 59
(28 %) patients achieved a pCR. Overall, the pCR rate was
significantly higher in patients who received bevacizumab
36 vs. 21 % for the non-bevacizumab arms; stratified
p = 0.019). In ER/PgR? disease (defined as [1 %
expression by immunohistochemistry (IHC) stain), there
was no statistically significant difference (bevacizumab
24 % vs. non-bevacizumab 18 %; p = 0.41), whereas the
pCR rate was statistically superior with bevacizumab in
TNBC (bevacizumab 59 % vs. non-bevacizumab 29 %;
p = 0.014). In non-IBC, the overall pCR rate was 29 %
with a higher rate in the patients treated with bevacizumab
(36 vs. 22 %; p = 0.037). A higher pCR rate for beva-
cizumab-treated patients with IBC (30 vs. 14 %) was not
statistically significant in this small patient subset
(p = 0.61). In a multivariate logistic regression analysis,
the increase in the pCR rate with bevacizumab was sta-
tistically significant (p = 0.023) adjusting for the type of
disease (IBC vs. not; ER/PgR? vs. TNBC) and neither
significantly interacted with treatment (p = 0.62 and
p = 0.19, respectively). In the non-bevacizumab arms,
pCR rates did not differ by treatment sequence (Arm 2
23 %, Arm 3 20 %, p = 0.82), justifying merging these
two control groups. Of the 195 patients who had surgery
488 Breast Cancer Res Treat (2016) 158:485–495
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recorded after neoadjuvant therapy, 41 (21 %) had a
lumpectomy rather than a mastectomy, which did not vary
by treatment (bevacizumab 22 %; no bevacizumab 20 %;
p = 0.86).
Secondary end points
Figure 3a shows the Kaplan–Meier comparison of OS.
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Randomized 99 116 215
Ineligible or withdrew consent 1 (1.0 %) 3 (2.6 %) 4 (1.9 %)
Analyzed 98 113 211
Age median (range) 51.7 (22–71) 51.3 (31–75) 51.5 (22–75)
Race
White 70 (71.4 %) 84 (74.3 %) 154 (73.0 %)
Black 20 (20.4 %) 18 (15.9 %) 38 (18.0 %)
Asian/Pacific Islander 5 (5.1 %) 6 (5.3 %) 11 (5.2 %)
Other/unknown 3 (3.1 %) 5 (4.4 %) 8 (3.8 %)
IBC or Non-IBC LABC
IBC 10 (10.2 %) 14 (12.4 %) 24 (11.4 %)
Non-IBC LABC 88 (89.8 %) 99 (87.6 %) 187 (88.6 %)
Hormone receptor status
Positive: ER? or PgR? 66 (67.3 %) 78 (69.0 %) 144 (68.2 %)
Negative: ER- and PR- (TNBC) 32 (32.7 %) 35 (31.0 %) 67 (31.8 %)
Breast cancer stage (1 missing)
IIB 35 (35.7 %) 52 (46.4 %) 87 (41.4 %)
IIIA 32 (32.6 %) 30 (26.8 %) 62 (29.5 %)
IIIB 29 (29.6 %) 24 (21.4 %) 53 (25.2 %)
IIIC 2 (2.0 %) 6 (5.4 %) 8 (3.8 %)
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up of about 3 years, with 3-year OS of 86 and 87 % for the
bevacizumab and non-bevacizumab groups, for a hazard
ratio (HR) of 0.84 (95 % CI 0.41–1.73, p = 0.64). When
separated by hormone receptor status, there were no sig-
nificant differences in OS between the bevacizumab and
non-bevacizumab groups. The survival curves suggest a
possible small benefit in the TNBC subset [Fig. 3b:
HR = 0.49 (95 % CI 0.19–1.29), log-rank p = 0.14] but
not in the ER/PgR? subset (Fig. 3c: HR = 1.85 (95 % CI
0.58–5.85), log-rank p = 0.33), but the interaction of
hormone receptor status and bevacizumab for OS was not
statistically significant (p = 0.14). In a landmarked anal-
ysis starting at 6 months (i.e., after surgery), having a pCR
was highly associated with subsequent OS for hormone
receptor-negative disease (HR = 0.15; 95 % CI
0.03–0.63), but not for hormone receptor-positive disease
(HR = 0.32; 95 % CI 0.04–2.50).
Event-free survival (EFS) also showed no significant
difference by treatment (Fig. 4a: p = 0.71; HR = 0.89;
95 % CI 0.48–1.65). When separated by hormone
receptor status, there were no significant differences for
EFS, but in TNBC there was a trend favoring the
bevacizumab arm [Fig. 4b: HR = 0.46 (95 % CI
0.20–1.05), log-rank p = 0.06] which was not seen in
ER/PgR? patients [Fig. 4c: HR = 2.20 (95 % CI
0.84–5.78), log-rank p = 0.10], and the interaction of
treatment and receptor status was statistically significant
for EFS (p = 0.028).
Treatment delivery and toxicity
Overall, Grade 3/4 events were common and did not differ
between the bevacizumab and non-bevacizumab arms
(bevacizumab 67 %; non-bevacizumab 65 %) (Table 3).
Grade 4 toxicities were seen in 19 (21 %) of patients in the
bevacizumab arm (two with sepsis, one with respiratory
failure, one with bilateral pulmonary emboli and deep vein
thrombosis, and 17 with hematologic events that included
anemia, febrile neutropenia, or thrombocytopenia). On the
other hand, 20 (19 %) patients in the non-bevacizumab arm
experienced Grade 4 events (one with heart failure, infec-
tious enterocolitis, sepsis, and respiratory failure, one with
dyspnea, one with Grade 4 anemia and hypercalcemia, one
with anemia and febrile neutropenia, and 17 with other
hematologic toxicities).
Discussion
We demonstrate that the addition of bevacizumab to
neoadjuvant chemotherapy significantly increased the pCR
rate in patients with LABC/IBC without significant addi-
tional toxicity, and that this increase was more pronounced
in patients with TNBC. These data suggest that the addition
of bevacizumab to anthracycline- and taxane-based
chemotherapy enhances its cytotoxicity.
The addition of bevacizumab to chemotherapy in
patients with metastatic breast cancer was initially
approved by the FDA on the basis of improvements in
response rate and PFS, but this approval was withdrawn
when these studies failed to demonstrate improvement in
OS [40], while the European Medicines Agency (EMA)
has approved its use with paclitaxel and capecitabine.
Meanwhile, four large randomized trials, in addition to
S0800, have investigated the addition of bevacizumab to
neoadjuvant chemotherapy for breast cancer [40–43]. All
have reported a significant benefit with the addition of
bevacizumab to anthracycline/taxane-based chemotherapy
(Table 4). As in our trial, GeparQuinto, CALGB 40603,
and ARTemis demonstrated a significant increase in the
pCR rate in patients with TNBC, while NSABP B-40
demonstrated a higher pCR rate with bevacizumab in ER/
Table 2 Primary outcome of
pathological complete response












Status at surgery postchemo
No surgery/incomplete report 7 (7.1 %) 10 (8.9 %) 17 (8.0 %)
Residual disease 56 (57.1 %) 79 (69.9 %) 135 (64.0 %)
Pathological complete response 35 (35.7 %) 24 (21.2 %) 59 (28.0 %)
Number with pCR (rates)
Overall 35/98 (35.7 %) 24/113 (21.2 %) 59/211 (28.0 %)
IBC 3/10 (30.0 %) 2/14 (14.3 %) 5/24 (20.8 %)
Non-IBC LABC 32/88 (36.4 %) 22/99 (22.2 %) 54/187 (28.9 %)
ER/PgR-positive 16/66 (24.2 %) 14/78 (18.0 %) 30/144 (20.8 %)
TNBC 19/32 (59.4 %) 10/35 (28.6 %) 29/67 (43.3 %)
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PgR? breast cancer but no statistically significant differ-
ence in TNBC.
Our EFS and OS results failed to demonstrate significant
differences favoring the addition of bevacizumab for the
overall study population, but in the relatively small
(n = 67) TNBC subset, the EFS and OS hazard ratios trend
in favor of the bevacizumab arm (HR 0.46, p = 0.06 and
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Fig. 3 Overall survival. Time from randomization to death due to
any cause. a Overall survival for all patients. b Overall survival for
patients with triple-negative (ER- and PgR-) disease. c Overall




















32 31 25 14 5 0Bevacizumab
35 26 21 10 3 0No Bevacizumab
Number at risk
0 1 2 3 4 5
Years since Randomization
No bevacizumab (n=35, 16 events)
Bevacizumab      (n=32, 9 events)
Stratified log-rank p = 0.06
HR-Negative




















66 62 57 32 11 0Bevacizumab
78 76 69 46 17 1No Bevacizumab
Number at risk
0 1 2 3 4 5
Years since Randomization
No bevacizumab (n=78, 8 events)
Bevacizumab      (n=66, 11 events)
Stratified log-rank p = 0.10
HR-Positive




















98 93 82 46 16 0Bevacizumab
113 102 90 56 20 1No Bevacizumab
Number at risk
0 1 2 3 4 5
Years since Randomization
No bevacizumab (n=113, 24 events)
Bevacizumab      (n=98, 20 events)
Stratified log-rank p = 0.71
Event-Free Survival by Randomized TreatmentA
B
C
Fig. 4 Event-free survival. Time from randomization to progression,
recurrence, or death due to any cause. a Event-free survival for all
patients. b Event-free survival for patients with triple-negative (ER-
and PgR-) disease. c Event-free survival for patients with ER? or
PgR? disease
Breast Cancer Res Treat (2016) 158:485–495 491
123
for these endpoints trend negatively in the larger ER/
PGR? population (HR 2.20, p = 0.10 and HR 1.85,
p = 0.33, respectively). None of the neoadjuvant studies
was powered to definitely demonstrate an EFS or OS
benefit for the addition of bevacizumab, overall or in the
TNBC population. The only study to show a survival
benefit with bevacizumab was NSABP B-40, which was
also the only one in which patients received bevacizumab
in the adjuvant as well as the neoadjuvant settings; as with
their pCR data, the survival benefit was seen only in the
ER/PgR? subset, and OS improvement was reported
despite the absence of significant improvement in DFS
[44]. The addition of bevacizumab also failed to improve
DFS or OS in two sizable trials in the adjuvant setting
[19, 20]; however, these trials were comprised largely of
lower risk patients, and in E5103 the improvement in DFS
with bevacizumab for TNBC approached significance (HR
0.77, 95 % CI 0.58–1.03).
These studies suggest that bevacizumab may be most
helpful in patients with high-risk cancers, defined by both
clinical stage and subtype. We have failed to identify any
subset of breast cancer patients most likely to benefit from
bevacizumab [22, 45]. In CALGB 40603, a randomized
phase II limited to stage II-III TNBC, investigators studied
how intrinsic subtype assigned by PAM50 and other gene
signatures affected the impact of bevacizumab on pCR rates
[46]. In basal-like cancers, the addition of bevacizumab
significantly increased pCR in the breast (64 vs 45 %) and
the breast/axilla (57 vs 43 %) rates, while paradoxically
lowering pCR rates in relatively small (12.7 %) number of
non-basal-like cancers, resulting in a significant interaction
between subtype and bevacizumab-specific pCR benefit
(p = 0.02).mRNA signatures for high proliferative rate, low
estrogen signaling, and high TP53 mutation were also
associated with greater pCR benefit with the addition of
bevacizumab, suggesting that even within TNBC there are
biologically defined patient subsets that may benefit differ-
entially from this agent. Similar analyses are underway for
S0800, and will be reported separately. If confirmed, these
findings could suggest that identifying and excluding a bio-
logically defined subset of ‘bevacizumab-resistant’ patients
lead to positive DFS and OS results from studies of beva-
cizumab in the adjuvant or neoadjuvant settings.
We also hypothesize that bevacizumab may have had
activity in our study because of the unique eligibility
requirement for LABC/IBC. Several studies have shown
that such extensive tumors with high levels of neoangio-
genesis are more likely to benefit from the addition of
bevacizumab to chemotherapy than early-stage cancers
with lower levels of tumor vasculature [1, 8–11, 47].
Therefore, we propose that perhaps these patients are
particularly susceptible to an antiangiogenic agent such as
bevacizumab.
Our study has several limitations. The power of a trial to
detect survival improvement from (neo) adjuvant
chemotherapy is influenced by the subtype composition of












Any event 64 (67 %) 69 (63 %) 133 (65 %)
ARDS 1 (1 %) 0 (0 %) 1 (1 %)
Diarrhea 3 (3 %) 2 (2 %) 5 (2 %)
Dyspnea 3 (3 %) 1 (1 %) 4 (2 %)
Enterocolitis, infectious 0 (0 %) 2 (2 %) 2 (1 %)
Hand foot syndrome 1 (1 %) 2 (2 %) 3 (1 %)
Heart failure 0 (0 %) 1 (1 %) 1 (1 %)
Hematologic events (including anemia,
febrile neutropenia, thrombocytopenia)
44 (46 %) 39 (35 %) 83 (40 %)
Hypercalcemia 0 (0 %) 1 (1 %) 1 (1 %)
Hypertension 7 (7 %) 3 (3 %) 10 (5 %)
Nausea 6 (6 %) 9 (8 %) 15 (7 %)
Pain 2 (2 %) 4 (4 %) 6 (3 %)
Respiratory failure 1 (1 %) 1 (1 %) 2 (1 %)
Sepsis 2 (2 %) 1 (1 %) 3 (1 %)
Thromboembolic event 1 (1 %) 2 (2 %) 3 (1 %)
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the accrued patients [48, 49]. Slightly more than two-
thirds of our patients had ER/PgR? cancers. Not only are
these patients much less likely to achieve a pCR, they
also have a better prognosis than TNBC and other more
aggressive breast cancer subtypes. Nearly 80 % of our
ER/PgR? patients, across all treatment arms, were alive
and free of disease recurrence at 4 years; EFS was only
50 % in TNBC patients assigned to the control arm,
almost sufficient for demonstrating a significant benefit in
a small cohort. Effective postneoadjuvant therapy, espe-
cially adjuvant endocrine therapy in ER/PgR? cancers,
improves outcomes in patients with residual disease and
thus diminishes the impact of a more effective neoadju-
vant regimen.
In summary, we find the trend favoring improvement in
EFS in our high-risk TNBC subset encouraging and
believing that the addition of bevacizumab to chemother-
apy in the neoadjuvant setting for these patients warrants
further investigation. While the role of bevacizumab
remains uncertain due to the lack of OS improvement in
several studies that included a high proportion of low- to
moderate-risk patients, the consistent association between
the addition of bevacizumab with higher response and pCR
rates in metastatic and neoadjuvant trials is intriguing and
underscores the importance of finding predictive
biomarkers for this drug. Our results also suggest that it
may worth re-evaluating the role of bevacizumab in locally
advanced TNBC.
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S0800 (ypT0, ypTis, ypN0) 3 years 3 years
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Appendix: Surgical procedure
Identification of the tumor bed was done by placement of
clips by core needle biopsy prior to treatment. However, in
the absence of a clip, detailed information about the loca-
tion (quadrant, clock face, distance from nipple) and the
presence of any other identifiable features (e.g., calcifica-
tions) was required to identify the tumor bed. Axillary
staging requirements were as noted previously. Also, a
detailed procedure for evaluation of surgical specimens
following neoadjuvant therapy was described. Specimens
were oriented with sutures by the surgeon following
removal. The surgeon and breast pathologist were required
to confer to ensure optimal evaluation of the primary tumor
site for possible pCR. (1) In cases showing significant
clinical response, each specimen was inked using multiple
colors to identify each face of the specimen and then sec-
tioned into 3–5 mm slices. The sliced specimen was
radiographed and a radiologist reviewed the films to
determine the presence and extent of residual tumor. The
pathologist examined the sliced specimen grossly to iden-
tify suspicious areas and noted their proximity to margins.
The radiographic and pathological evaluation was dis-
cussed with the surgeon who decided whether additional
margins should be obtained. Permanent paraffin sections of
the suspicious areas and margins were obtained. The
number of sections taken was based on the gross inspec-
tion, radiologic features, and size of the resection speci-
men. The entire radiographic abnormality as well as firm
and suspicious-appearing breast tissue was submitted for
histologic evaluation. In general, for non-palpable (clinical
complete response) cases, at least 10–15 blocks were
examined to assess the presence of residual microscopic
disease; (2) in cases with residual palpable mass (partial
clinical response or no response in the breast), the resection
specimen was inked and sectioned into 3–5 mm slices. The
pathologist examined the slices and determined the tumor
size on gross evaluation and confirmed the tumor size by
microscopic evaluation; (3) Evaluation of axillary lymph
nodes regardless of response. All axillary lymph nodes
were also carefully evaluated by serial gross sectioning.
One or two representative histologic sections were evalu-
ated for lymph nodes that contain grossly identifiable
metastatic carcinoma. The lymph nodes that do not show
grossly identifiable tumor were submitted for histologic
evaluation in their entirety. One representative histologic
section was evaluated per paraffin block.
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